Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The **Nestorone Ring** is a progestin-only contraceptive vaginal ring developed by the Population Council, designed for continuous use over 3 or 6 months to provide contraception for women of reproductive age, including those with high BMI or breastfeeding postpartum. It delivers **segesterone acetate (Nestorone or NES)**, a potent 19-norprogesterone derivative that is not orally active but highly effective via vaginal delivery, inhibiting ovulation without estrogenic side effects like increased VTE risk associated with ethinyl estradiol. Clinical trials, including Phase 2b studies by the NICHD network, are evaluating its safety, efficacy, and bleeding patterns, with advantages such as no refrigeration need, user control, minimized bone density impact, and rapid fertility return.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nestorone Ring.